Shaikh Sibhghatulla, Lee Eun Ju, Ahmad Khurshid, Choi Inho
Department of Medical Biotechnology, Yeungnam University, Gyeongsan, Republic of Korea.
Research Institute of Cell Culture, Yeungnam University, Gyeongsan, Republic of Korea.
Front Mol Biosci. 2024 Jul 3;11:1440132. doi: 10.3389/fmolb.2024.1440132. eCollection 2024.
Licochalcone B (LicB), a chalcone derived from and glabra, has received considerable attention due to its diverse pharmacological properties. Accumulated data indicates that LicB has pharmacological effects that include anti-cancer, hepatoprotective, anti-inflammatory, and neuroprotective properties. The action mechanism of LicB has been linked to several molecular targets, such as phosphoinositide 3-kinase/Akt/mammalian target of rapamycin, p53, nuclear factor-κB, and p38, and the involvements of caspases, apoptosis, mitogen-activated protein kinase-associated inflammatory pathways, and anti-inflammatory nuclear factor erythroid 2-related factor 2 signaling pathways highlight the multifaceted therapeutic potential of LicB. This review systematically updates recent findings regarding the pharmacological effects of LicB, and the mechanistic pathways involved, and highlights the potential use of LicB as a promising lead compound for drug discovery.
甘草查尔酮B(LicB)是一种从光果甘草中提取的查尔酮,因其多样的药理特性而备受关注。积累的数据表明,LicB具有抗癌、保肝、抗炎和神经保护等药理作用。LicB的作用机制与多个分子靶点有关,如磷脂酰肌醇3激酶/蛋白激酶B/雷帕霉素哺乳动物靶蛋白、p53、核因子κB和p38,半胱天冬酶、细胞凋亡、丝裂原活化蛋白激酶相关炎症途径以及抗炎核因子红细胞2相关因子2信号通路的参与突出了LicB多方面的治疗潜力。本文综述系统地更新了关于LicB药理作用及其涉及的作用机制途径的最新研究结果,并强调了LicB作为一种有前景的药物发现先导化合物的潜在用途。